Patent application number | Description | Published |
20100201399 | Driver Circuit for a Two-Wire Conductor and Method for Generating Two Output Currents for a Two-Wire Conductor - A driver circuit and method for generating two complementary output currents from a two-state logic input signal at two outputs for connecting a two-wire conductor provide the following actions: generating from the input signal, an output signal at each output, the amperage of one of the output currents being adjustable by a control signal; analyzing each voltage materializing at the outputs; generating an error signal as a function of the output voltages within each of at least two time slots subsequent to a change in state of the input signal; caching the error signals or signals derived therefrom and adjusting, as a function of cached error signals or of the cached signals as a function thereof, the output current in corresponding time slots subsequent to a resulting change in state of the input signal. | 08-12-2010 |
20140223050 | Receiver Architecture - In accordance with an embodiment, a receiver includes a first state machine configured to be coupled to a bus. The first state machine is configured to determine that a first output signal is a first symbol if a first received bus signal transitions from a first bus state to a second bus state and stays in the second bus state for less than a first predetermined period of time, and the first output signal is a second symbol if the first received bus signal transitions from the first bus state to the second bus state and stays in the second bus state for at least the first predetermined period of time. | 08-07-2014 |
20140355158 | SHUTDOWN PROTECTION FOR BUS LINE DRIVERS - An electrical circuit for driving a bus is described that includes a plurality of branches coupled to at least one signal line at a termination of the bus and a transmit data input configured to receive data that the electrical circuit drives across the bus. The electrical circuit also includes an over-current validation unit coupled to the transmit data input which is configured to validate an over-current condition detected at a first branch of the plurality of branches based at least in part on the data at the transmit data input. The electrical circuit also includes a branch control unit coupled to the over-current validation unit which is configured to disable at least one of the plurality of branches in response to a validated over-current condition at the first branch. | 12-04-2014 |
20140359190 | OVER-CURRENT DETECTION FOR BUS LINE DRIVERS - An electrical circuit for driving a bus is described that includes at least one branch coupled to at least one signal line at a termination of the bus and a transmit data input configured to receive data that the electrical circuit drives across the bus. The electrical circuit also includes a current detection unit coupled to the at least one branch, which is configured to detect a current through the at least one branch. The electrical circuit also includes an over-current determination unit coupled to both the current detection unit and the transmit data input. The over-current determination unit is configured to determine an over-current condition at the at least one branch based on the current at the at least one branch and the data at the transmit data input. | 12-04-2014 |
Patent application number | Description | Published |
20080260755 | Proteolytically cleavable fusion proteins with high molar specific activity - The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV. | 10-23-2008 |
20080261238 | Method for Differentiation of Factor XIII Deficiency States in Relation to Fibrinogen Deficiency States Using Thrombelastographic Techniques - The invention relates to a method for determining a factor XIII deficiency, a method for determining a fibrinogen deficiency, and a method for differentiating between a factor XIII deficiency and a fibrinogen deficiency by means of thrombelastographic techniques. On the basis of the evaluation of the thrombelastographic parameters, a rapid and a selective substitution of factor XIII and/or of fibrinogen in deficiency states is possible. | 10-23-2008 |
20090042787 | Proteolytically cleavable fusion proteins with high molar specific activity - The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV (SEQ ID NO: 94). | 02-12-2009 |
20100120664 | MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE - The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences. | 05-13-2010 |
20100222554 | Method of Increasing the In Vivo Recovery of Therapeutic Polypeptides - The present invention relates to the field of modified therapeutic polypeptides with increased in vivo recovery compared to their non-modified parent polypeptide. I.e., the invention relates to fusions of therapeutic polypeptides with recovery enhancing polypeptides connected directly or optionally connected by a linker peptide. | 09-02-2010 |
20110183907 | FACTOR VIII, VON WILLEBRAND FACTOR OR COMPLEXES THEREOF WITH PROLONGED IN VIVO HALF-LIFE - The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences. | 07-28-2011 |
20110189182 | PROTEOLYTICALLY CLEAVABLE FUSION PROTEINS WITH HIGH MOLAR SPECIFIC ACTIVITY - The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV. | 08-04-2011 |
20130337532 | THERAPEUTIC POLYPEPTIDES WITH INCREASED IN VIVO RECOVERY - The present invention relates to the field of modified therapeutic polypeptides with increased in vivo recovery compared to their non-modified parent polypeptide. For example, the invention relates to fusions of therapeutic polypeptides with recovery enhancing polypeptides connected directly or optionally connected by a linker peptide. | 12-19-2013 |
20140072561 | FACTOR VIII, VON WILLEBRAND FACTOR OR COMPLEXES THEREOF WITH PROLONGED IN VIVO HALF-LIFE - The present invention relates to modified nucleic acid sequences coding for coagulation factor VIII (FVIII) and for von Willebrand factor (VWF) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding FVIII sequences that result in improved expression yield. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such modified nucleic acid sequences. | 03-13-2014 |
20140248686 | THERAPEUTIC POLYPEPTIDES WITH INCREASED IN VIVO RECOVERY - The present invention relates to the field of modified therapeutic polypeptides with increased in vivo recovery compared to their non-modified parent polypeptide. For example, the invention relates to fusions of therapeutic polypeptides with recovery enhancing polypeptides connected directly or optionally connected by a linker peptide. | 09-04-2014 |
20140249086 | Method for Improving the Stability of Purified Factor VIII After Reconstitution - The present invention relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing of the Factor VIII molecule. The invention further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection. | 09-04-2014 |
20140273096 | MODIFIED COAGULATION FACTORS WITH PROLONGED IN VIVO HALF-LIFE - The present invention relates to nucleic acid sequences coding for modified coagulation factors, preferably coagulation factor VIII, and their derivatives; recombinant expression vectors containing such nucleic acid sequences; host cells transformed with such recombinant expression vectors; and recombinant polypeptides and derivatives coded for by said nucleic acid sequences, whereby said recombinant polypeptides and derivatives have biological activities and prolonged in vivo half-lives compared to the unmodified wild-type proteins. The invention also relates to corresponding sequences that result in improved in vitro stability. The present invention further relates to processes for the manufacture of such recombinant proteins and their derivatives. The invention also relates to a transfer vector for use in human gene therapy, which comprises such nucleic acid sequences. | 09-18-2014 |
20140315815 | USE OF SULFATED GLYCOSAMINOGLYCANS FOR IMPROVING THE BIOAVAILABILITY OF FACTOR VIII - The present invention relates to pharmaceutical preparations comprising one or more Factor VIII and a sulfated glycosaminoglycan for increasing the bioavailability of Factor VIII upon non-intravenous administration. The invention further relates to the combined use of Factor VIII and a sulfated glycosaminoglycan for the treatment and prevention of bleeding disorders, whereby the bioavailability of Factor VIII is increased, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by coadminstration of a sulfated glycosaminoglycan. | 10-23-2014 |
20150023946 | Combined Use of a Sulfated Glycosaminoglycan and a Hyaluronidase for Improving the Bioavailability of Factor VIII - The present invention relates to pharmaceutical preparations comprising Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders. The invention further relates to the combined use of a Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the treatment and prevention of bleeding disorders, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by co-adminstration of a sulfated glycosaminoglycan and a hyaluronidase. | 01-22-2015 |